Compagnie Lombard Odier SCmA Boosts DexCom Holdings

The institutional investor increased its stake in the medical device company by nearly 19% in Q4 2025.

Apr. 2, 2026 at 8:34am

Compagnie Lombard Odier SCmA, an institutional investor, boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 18.9% during the fourth quarter of 2025, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The firm now owns 216,798 shares of the medical device company's stock, worth approximately $14.4 million.

Why it matters

DexCom is a leading manufacturer of continuous glucose monitoring (CGM) systems, which are critical devices for diabetes management. The increase in Compagnie Lombard Odier SCmA's stake suggests the institutional investor sees long-term growth potential in DexCom as the CGM market continues to expand.

The details

According to the 13F filing, Compagnie Lombard Odier SCmA purchased an additional 34,406 shares of DexCom during the fourth quarter, bringing its total ownership to 0.06% of the company's outstanding stock. The move comes as DexCom has faced some analyst downgrades and a drop in its stock price over the past year, despite the company's strong financial performance and growing market share in the CGM space.

  • Compagnie Lombard Odier SCmA filed its 13F report for the fourth quarter of 2025 on April 2, 2026.

The players

Compagnie Lombard Odier SCmA

An institutional investor and asset management firm based in Switzerland.

DexCom, Inc.

A medical device company that develops and manufactures continuous glucose monitoring (CGM) systems for people with diabetes.

Got photos? Submit your photos here. ›

The takeaway

Compagnie Lombard Odier SCmA's increased stake in DexCom suggests the firm sees long-term growth potential in the medical device company, even as it has faced some short-term headwinds. The move highlights the institutional investor's confidence in DexCom's ability to maintain its leadership position in the expanding CGM market.